A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3)

drug protocol number
D5136C00009
drug sponsor
Astrazeneca
drug study
Ticagrelor
drug trial site
KFMC
drug status
Ongoing
drug phase